ACR Convergence 2025

October 24-29, 2025. Chicago, Illinois.

View by Number View by Title View Sessions

Abstract Number: 2358

Bimekizumab Demonstrated Early and Sustained Efficacy Regardless of Baseline Characteristics in Patients with Active Psoriatic Arthritis: Pooled Post Hoc Results up to 1-Year from Two Phase 3 Studies
Abstract Number: 2359

Combination Of TNF Inhibitors And NSAIDs Versus TNF Inhibitors Alone On The Progression Of Structural Damage In The Spine And Hip: a Retrospective Study In 262 Patients With Radiographic Axial Spondyloarthritis
Abstract Number: 2360

Treatment adherence in ankylosing spondylitis: A comparison of TNFi, IL-17i, and JAKi using real-world data
Abstract Number: 2361

Secondary Outcomes from a Series of N-of-1 NSAID Trials in Axial Spondyloarthritis: Functional, Quality-of-Life, and Safety Results from a Bayesian Analysis
Abstract Number: 2362

Long-Term Efficacy and Safety of Risankizumab for csDMARD-IR Patients With Active Psoriatic Arthritis: 244-Week Results From the KEEPsAKE 1 Trial
Abstract Number: 2363

Impact of Biologic Therapies on Cardiovascular and Venous Thromboembolic Events in Psoriatic Arthritis: Real-World Evidence
Abstract Number: 2364

Real-World Characteristics and Treatment Patterns of Difficult-to-Treat Psoriatic Arthritis
Abstract Number: 2365

Sustained Efficacy up to 3 Years with Bimekizumab Treatment Across GRAPPA Core Domains in Patients with Psoriatic Arthritis: Long-Term Results from Two Phase 3 Trials
Abstract Number: 2366

Association Between Skin and Joint Symptom Control and Patient-Reported Pain and Health Status Among Patients with Psoriatic Arthritis in the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry Initiating Biologic or Targeted Synthetic Disease-Modifying Antirheumatic Drugs
Abstract Number: 2367

Real-World Effectiveness of Risankizumab on Axial Symptoms in Biologic-Naïve Patients With Psoriatic Arthritis in the United States and Europe
Abstract Number: 2368

Inhibition of Structural Damage Progression with Guselkumab, a Selective IL-23i, in Participants with Active PsA: Results Through Week 24 of the Phase 3b, Randomized, Double-Blind, Placebo-Controlled APEX Study
Abstract Number: 2369

Real-World On-Label Treatment Persistence Through 24 Months in Biologic-Naïve and Biologic-Experienced Patients with Psoriatic Arthritis: Comparison of Guselkumab versus Subcutaneous Interleukin-17A Inhibitors
Abstract Number: 2370

Comparative Efficacy and Safety of IL-17 Inhibitors Versus Adalimumab in Biologic-Naive Psoriatic Arthritis Patients: A Meta-Analysis of Randomized Controlled Trials
Abstract Number: 2371

A Predictive Model Combining Clinical and Laboratory Parameters to Predict anti-TNF Response in Patients with Psoriatic Arthritis
Abstract Number: 2372

Treatment Outcome and Persistence of IL-23 Inhibitors in Real World Cohort of PsA Patients- A Retrospective Study

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].